Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease crawled time : 09:00 save search
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Published: 2024-02-13 (Crawled : 09:00) - biospace.com/
VRTX | $393.1 -0.27% -0.27% 880K
|
Health Technology
|
| O: -0.28%
H: 0.49%
C: -0.32%
first disease cell treatment
Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis
Published: 2023-10-11 (Crawled : 09:00) - biospace.com/
BMY | $47.84 -0.87% -0.02% 12M
|
Health Technology
|
| O: 0.16%
H: 0.73%
C: 0.3%
disease sclerosis
Reshaping Cystic Fibrosis Disease Landscape Report | Epidemiology Study, Drug Insights, Unmet Needs Analysis, KOL Perspectives Product Launch Services, and Regulatory Consulting |Disease Landscape Insights
Published: 2023-10-09 (Crawled : 09:00) - prnewswire.com
ALPMY | News | $9.34 -1.11% 690K
|
Manufacturing
|
| O: -0.04%
H: 0.77%
C: 0.7%
drug disease report fibrosis
Navigating the Anaemia Disease Landscape: Market Insight Epidemiology, Forecast, & Market Entry Strategies | Disease Landscape Insights
Published: 2023-10-02 (Crawled : 09:00) - prnewswire.com
BIIB | $192.13 -1.55% -1.57% 1.3M
|
Health Technology
|
| O: -0.45%
H: 0.39%
C: -1.17%
disease market
Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-07-17 (Crawled : 09:00) - biospace.com/
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
REGN | $901.27 0.8% 0.78% 470K
|
Health Technology
|
| O: 0.05%
H: 1.33%
C: 0.38%
ALNY | $145.23 -1.02% -1.03% 500K
|
Health Technology
|
| O: 5.53%
H: 5.23%
C: -2.49%
disease alzheimer’s positive results
Stargardt Disease Therapeutics Market: Special and Wide … – Digital Journal
Published: 2023-06-23 (Crawled : 09:00) - spacfeed.com
CLOV | $0.6233 -0.27% -0.27% 6.2M
|
|
| O: -0.26%
H: 8.91%
C: 0.74%
disease therapeutics
Gilead to Present Latest Liver Disease Research at the European Association for the Study of the Liver (EASL) Congress 2023
Published: 2023-06-14 (Crawled : 09:00) - biospace.com/
GILD | $66.94 -0.55% -0.55% 5.3M
|
Health Technology
|
| O: -0.52%
H: 0.46%
C: -0.12%
liver disease association research study
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
Published: 2023-06-09 (Crawled : 09:00) - biospace.com/
VRTX | $393.1 -0.27% -0.27% 880K
|
Health Technology
|
| O: 0.28%
H: 0.44%
C: 0.18%
CRSP M | $55.56 -4.14% -4.32% 1.4M
|
Health Technology
|
| O: 8.5%
H: 0.52%
C: -9.82%
disease association positive cell trials results
Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson’s Disease
Published: 2023-04-04 (Crawled : 09:00) - biospace.com/
ADXN | $22.8 0.89% 0.88% 16K
|
Health Technology
|
| O: 7.68%
H: 2.8%
C: -13.72%
disease parkinson’s
Neurodegenerative Disease Therapeutics Industry Expected to Reach USD 28.15 billion by 2030 - Grand View Research, Inc.
Published: 2023-03-21 (Crawled : 09:00) - prnewswire.com
JNJ | News | $144.77 0.22% -0.01% 9.3M
|
Health Technology
|
| O: 0.07%
H: 0.08%
C: -0.07%
disease expected therapeutics neurodegenerative
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Nine Patients
Published: 2022-10-12 (Crawled : 09:00) - biospace.com/
SGMO | $0.513 -5.35% -5.65% 1.2M
|
Health Technology
|
| O: -0.21%
H: 0.63%
C: 0.0%
disease therapeutics phase 1
Alzheimer's Disease Therapeutics Market to record USD 3.99 Bn growth -- Driven by the availability, research, and development of novel biomarkers
Published: 2022-09-28 (Crawled : 09:00) - prnewswire.com
GIKLY | $4.6 132.75% 4.5K
|
Manufacturing
|
| O: -6.72%
H: 0.0%
C: 0.0%
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: 0.0%
VTRS | $11.095 -0.22% -0.23% 6.1M
|
Health Technology
|
| O: 0.94%
H: 2.22%
C: 1.99%
NVS | News | $93.08 -0.13% 0.86% 1.2M
|
Health Technology
|
| O: 1.46%
H: 1.25%
C: 0.77%
ABBV | $164.25 1.05% -0.76% 4M
|
Health Technology
|
| O: 1.76%
H: 0.76%
C: 0.26%
DNLI | $16.81 -3.06% -3.15% 1.4M
|
Health Technology
|
| O: 6.45%
H: 16.46%
C: 10.57%
BIIB | $192.13 -1.55% -1.57% 1.3M
|
Health Technology
|
| O: 43.06%
H: 0.17%
C: -2.24%
disease alzheimer's therapeutics biomarkers growth market
ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician’s Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer
Published: 2022-08-15 (Crawled : 09:00) - biospace.com/
AZN | $68.53 0.39% 0.39% 3.7M
|
Health Technology
|
| O: 0.92%
H: 0.22%
C: -0.65%
enhertu treatment disease trial positive cancer her2- her2 metastatic breast cancer
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
Published: 2022-08-05 (Crawled : 09:00) - biospace.com/
ACAD | News | $17.2 0.7% 0.7% 1M
|
Health Technology
|
| O: -2.62%
H: 11.57%
C: 8.09%
treatment fda drug disease application alzheimer’s response
New release of Philips EchoNavigator helps interventional teams treat structural heart disease with greater ease and efficiency
Published: 2022-05-16 (Crawled : 09:00) - globenewswire.com
PHG | News | $20.15 -0.89% 0.0% 790K
|
Health Technology
|
| O: 2.26%
H: 1.76%
C: 1.35%
disease heart
Bilirubin Blood Test Market 2022-2026 | Increasing Prevalence of Jaundice and Liver Diseases to Boost Growth | Technavio
Published: 2022-05-09 (Crawled : 09:00) - prnewswire.com
RYLPF | News | $20.515 3.85% 7K
|
Health Technology
|
| O: -2.42%
H: 0.0%
C: -2.55%
TMO | News | $547.25 -1.32% -0.02% 1.6M
|
Health Technology
|
| O: -1.05%
H: 0.0%
C: -3.95%
ABT | News | $105.9 -3.03% 0.07% 12M
|
Health Technology
|
| O: -2.03%
H: 0.0%
C: 0.0%
blood liver test growth market disease
Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
Published: 2022-04-26 (Crawled : 09:00) - biospace.com/
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: 3.08%
H: 0.0%
C: 0.0%
valneva disease report vaccine positive phase 2
Nirsevimab significantly protected infants against RSV disease in Phase 3 trial
Published: 2022-03-03 (Crawled : 09:00) - biospace.com/
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -6.92%
H: 1.86%
C: 1.86%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
trial disease phase 3
CORRECTING and REPLACING CANbridge Announces Approval of CAN108 for Rare Liver Disease, Alagille Syndrome, Under the Early and Pilot Implementation Policy in Boao Lecheng International Medical Tourism Pilot Zone
Published: 2022-02-25 (Crawled : 09:00) - biospace.com/
MIRM | $23.87 -0.58% -0.59% 330K
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: 0.0%
can108 rare liver approval disease liver disease one ism syndros
Relief Announces That Collaboration Partner, Acer Therapeutics, was Issued U.S. Patent 11,202,767 Covering ACER-001 Methods of Use for Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
Published: 2022-02-01 (Crawled : 09:00) - biospace.com/
RLFTF | $1.35 11.45% 3.5K
|
n/a
|
| O: -5.33%
H: 5.63%
C: 3.52%
acer-001 urea urine treatment order ces patent therapeutics disease collaboration
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.